8-K: Adtalem Global Education Reports Strong Q1 FY26 Results

Adtalem Global Education announced robust first quarter fiscal year 2026 results, with total enrollment up 8.0% and revenue increasing 10.8% year-over-year, while maintaining its full-year guidance.

Summary

• Total student enrollment reached 97,359, an increase of 8.0% year-over-year.
• Revenue for the quarter was $462.3 million, up 10.8% year-over-year.
• Diluted earnings per share were $1.67, with adjusted diluted EPS at $1.75, representing a 35.7% growth year-over-year.
• GAAP net income stood at $61.8 million.
• Adjusted EBITDA was $112.0 million, an increase of 15.8% year-over-year.
• Chamberlain University achieved its eleventh consecutive quarter of total enrollment growth, up 2.2% year-over-year.
• Walden University recorded its ninth consecutive quarter of total enrollment growth, up 13.6% year-over-year, reaching the highest total enrollment in the university's history.
• The Medical & Veterinary segment experienced its third consecutive enrollment cycle growth, up 2.4% year-over-year.
• Repurchased $8 million of shares in the first quarter, with $142 million remaining under the $150 million Board-authorized share repurchase program through May 2028.
• Increased the revolving credit facility by $100 million to $500 million and extended its maturity to August 2030.
• Repaid $50 million of outstanding Term Loan B balance on October 29, 2025.
• Net leverage was 0.6x as of September 30, 2025.
• Maintains fiscal year 2026 guidance for revenue between $1,900 million and $1,940 million, and adjusted earnings per share between $7.60 and $7.90.

Sentiment

Score: 9

Explanation: The filing reports strong financial and operational performance, including significant revenue and EPS growth, consistent enrollment increases across all segments, and strategic initiatives like AI integration and program expansion. The company also demonstrates disciplined capital allocation through share repurchases and debt repayment, while maintaining optimistic full-year guidance.

Positives

• Total student enrollment increased 8.0% year-over-year to 97,359.
• Revenue grew 10.8% year-over-year to $462.3 million.
• Adjusted diluted earnings per share increased 35.7% year-over-year to $1.75.
• Adjusted EBITDA rose 15.8% year-over-year to $112.0 million, with adjusted EBITDA margin improving to 24.2% from 23.2%.
• Chamberlain University achieved its eleventh consecutive quarter of total enrollment growth, up 2.2%.
• Walden University recorded its ninth consecutive quarter of total enrollment growth, up 13.6%, reaching its highest total enrollment in university history.
• The Medical & Veterinary segment saw its third consecutive enrollment cycle growth, up 2.4%.
• Repurchased $8 million of shares in Q1 FY2026, with $142 million remaining under the Board-authorized $150 million share repurchase program.
• Increased revolving credit facility by $100 million to $500 million and extended its maturity to August 2030.
• Repaid $50 million of outstanding Term Loan B balance.
• Strong net leverage of 0.6x as of September 30, 2025.
• Partnership with Google Cloud to co-develop a comprehensive AI credentials program for healthcare students and clinicians.
• Chamberlain University expanded its Practice Ready. Specialty Focused. (PRSF) model and its Bachelor of Science in Nursing (BSN) Online Option, which now serves over 4,000 students across 36 states.
• Walden University streamlined professional doctoral programs with a simplified single tuition price point, integrated Believe & Achieve Scholarship, and a newly designed capstone process.
• Ross University School of Medicine (RUSM) and American University of the Caribbean (AUC) expanded access to medical education through new partnerships with University of Wolverhampton, a leading Indian higher education institution, and ScribeAmerica.

Negatives

• Chamberlain University's operating income decreased 1.4% to $25.6 million, and adjusted operating income decreased 8.0% to $25.6 million.
• Chamberlain University's adjusted EBITDA decreased 5.1% to $35.1 million.
• Growth in pre-licensure nursing at Chamberlain University was partially offset by declines in post-licensure programs.

Risks

• Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those described.
• Important factors that could cause actual results to differ materially from expectations are disclosed in Item 1A. Risk Factors of the most recent Annual Report on Form 10-K and other SEC filings.

Future Outlook

Adtalem maintains its fiscal year 2026 guidance, projecting revenue in the range of $1,900 million to $1,940 million, which represents approximately 6.0% to 8.5% growth year-over-year. Adjusted earnings per share are expected to be in the range of $7.60 to $7.90, indicating approximately 14.0% to 18.5% growth year-over-year.

Management Comments

• "We delivered an outstanding start to Fiscal Year 2026—adjusted EPS up 35.7% and revenue up 10.8% marking our ninth consecutive quarter of enrollment growth."
• "With net leverage at 0.6x and strong free cash flow, we’re executing a disciplined capital allocation strategy that balances growth investment with shareholder returns."
• "We look forward to sharing our strategic vision and capital allocation framework at our Investor Day in February."
• "Our focus remains singular: creating sustainable, long-term shareholder value by serving as essential talent infrastructure for America’s healthcare workforce."

Industry Context

Adtalem Global Education positions itself as the largest provider of healthcare education in the U.S., actively addressing critical shortages in the healthcare workforce. Its strategic initiatives, such as the AI integration partnership with Google Cloud and the expansion of nursing programs (PRSF model, BSN Online Option), align with broader industry trends of technological advancement in education and the increasing demand for skilled healthcare professionals. The company's partnerships with other universities and ScribeAmerica further demonstrate efforts to expand access and create diverse pathways into medical education, directly responding to the evolving needs of the talent pipeline.

Legal Proceedings

• Income (loss) from discontinued operations includes expense from ongoing litigation costs and settlements related to divestitures.

Stakeholder Impact

• Shareholders: Positive impact due to strong financial performance, share repurchases, and maintained positive guidance, indicating potential for increased shareholder value.
• Students: Positive impact through expanded program offerings (e.g., BSN Online Option, PRSF model), streamlined doctoral programs, and new partnerships expanding access to medical education, as well as the development of an AI credentials program.
• Employees: Continued growth and strategic initiatives suggest stability and potential for professional development, especially with AI integration.
• Healthcare Industry: Positive impact by addressing critical workforce shortages through high-quality academic programs and innovative educational pathways.

Next Steps

• Host an Investor Day on Tuesday, February 24, 2026, to share strategic vision and capital allocation framework.
• Continue executing a disciplined capital allocation strategy that balances growth investment with shareholder returns.
• Continue serving as essential talent infrastructure for America's healthcare workforce.

Key Dates

Recommendation

The company delivered an outstanding first quarter with significant year-over-year growth in revenue (10.8%), adjusted EPS (35.7%), and adjusted EBITDA (15.8%). Enrollment growth is consistent across all segments, including record enrollment at Walden University. The company's strategic initiatives, such as AI integration and expansion of critical healthcare programs, position it well for future growth in a high-demand sector. Furthermore, a strong balance sheet with 0.6x net leverage, active share repurchases, and an increased credit facility demonstrate sound financial management and commitment to shareholder returns. Maintaining robust FY2026 guidance reinforces confidence in sustained performance. These factors collectively suggest strong upside potential.

Keywords

Healthcare education, Higher education, Adtalem, ATGE, Chamberlain University, Walden University, Medical education, Veterinary education, Enrollment growth, Financial results, Q1 FY2026, AI integration, Share repurchase, Debt repayment, Capital allocation